This article is more than 5 years old. Information may no longer be current.

Diabetic retinopathy severity remains decreased at year 3 in RISE, RIDE trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Regression of two steps in ETDRS severity level was maintained between months 24 and 36 in patients receiving continued ranibizumab treatment in the RIDE and RISE trials, a speaker said here.

“In contrast, the patients in the sham group, despite the initiation of ranibizumab between months 24 and 36, did not have a change in diabetic retinopathy severity level,” Michael S. Ip, MD, told colleagues at Retina Subspecialty Day preceding the joint meeting of the American Academy of Ophthalmology and Asia-Pacific Academy of Ophthalmology.

Michael S. Ip

In the RIDE and RISE trials, patients were randomized to receive 0.3 mg Lucentis (ranibizumab, Genentech), 0.5 mg ranibizumab or sham for treatment of diabetic macular edema to 24 months. At 24 months, patients in the sham arm began receiving active treatment.

“These data derived from two large randomized trials of ranibizumab for diabetic macular edema provide strong evidence that ranibizumab is effective in reducing diabetic retinopathy severity level,” Ip said.

The data further suggest that a delay in ranibizumab therapy results in a reduction in the chance to improve diabetic retinopathy severity level.

“It is unknown if a delay of less than 2 years would result in a similar loss of benefit in diabetic retinopathy severity level; however, the authors speculate that the longer the delay, the greater the loss of effect of ranibizumab on diabetic retinopathy severity level,” Ip said.

The study authors continue to recommend, as they did at 24 months, that ranibizumab or a combination of ranibizumab and focal laser be considered in eyes in which either therapy may be contemplated because of the potential for beneficial effects of ranibizumab on diabetic retinopathy severity level, Ip said.

Disclosure: Ip is a consultant or speaker for Allergan, Eye Technology, Genentech, NicOx, Notal Vision, QLT Phototherapeutics, Regeneron and Sirion.